Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02145182
Recruitment Status : Completed
First Posted : May 22, 2014
Results First Posted : December 17, 2018
Last Update Posted : December 17, 2018
Sponsor:
Collaborator:
CTI Clinical Trial and Consulting Services
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.

Condition or disease Intervention/treatment Phase
Delayed Graft Function Drug: Eculizumab Drug: Placebo Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 288 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multi-center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function.
Actual Study Start Date : August 21, 2014
Actual Primary Completion Date : November 22, 2016
Actual Study Completion Date : November 22, 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Eculizumab

Arm Intervention/treatment
Experimental: Active
Eculizumab was administered by intravenous (IV) infusion over 25-45 minutes (min) for 2 doses (on the day of transplant then 18-24 hours [h] later).
Drug: Eculizumab
Eculizumab is a complement component 5 inhibitor.
Other Name: Soliris

Placebo Comparator: Placebo
Placebo was administered by IV infusion over 25-45 min for 2 doses (on the day of transplant then 18-24 h later).
Drug: Placebo
0.9% sodium chloride




Primary Outcome Measures :
  1. Percentage Of Participants With Delayed Graft Function (DGF) In The First Seven Days Post-transplant [ Time Frame: First 7 days post transplantation ]
    Results are reported for the DGF composite endpoint, defined as the occurrence of DGF (dialysis for any reason in the first 7 days post transplantation), graft loss, death, or loss to follow-up (including discontinuation) in the first 7 days post transplantation and for each item of the composite endpoint. Loss to follow-up included withdrawal due to any reason other than death. The sum of the counts in the events that make up the DGF composite may be greater than the composite count, because a participant who experienced multiple events was only counted once in the composite.


Secondary Outcome Measures :
  1. Percentage Of Participants With DGF, Functional DGF, And Immediate Graft Function [ Time Frame: First 7 days post transplantation ]
    DGF was defined as a requirement for dialysis for any reason in the first 7 days post transplantation; functional DGF was defined as no need for dialysis during the first 7 days post transplantation and either (1) a <70% reduction in serum creatinine during the first 7 days post transplantation, or (2) failure of serum creatinine to decrease by at least 10% daily on 3 consecutive days, both measured during the first 7 days post transplantation. Blood and urine samples were collected, but because the study failed to demonstrate a treatment effect and the program subsequently lost funding, the collected data from the samples could not be analyzed to generate summary level data. As such, the data set for this secondary outcome measure cannot be summarized.

  2. Percentage Of Participants Who Required Dialysis Post Transplantation [ Time Frame: First 30 days post transplantation ]
    The need for dialysis was assessed by evaluation of renal function; this included urine volume, blood urea nitrogen, serum creatinine, and, starting on Day 2, the creatinine reduction ratio. Blood and urine samples were collected, but because the study failed to demonstrate a treatment effect and the program subsequently lost funding, the collected data from the samples could not be analyzed to generate summary level data. As such, the data set for this secondary outcome measure cannot be summarized.

  3. Estimated Glomerular Filtration Rate (eGFR) [ Time Frame: Day 28 post transplantation ]
    The eGFR was calculated by using the Modification of Diet in Renal Disease 7 equation at Day 28 post transplantation. The equation requires serum creatinine, age, ethnicity, gender, blood urea nitrogen, and albumin. The eGFR was calculated retrospectively from participant demographics and laboratory chemistries and is reported in mL/min/square meter (m^2).

  4. Percentage Of Participants With Rejection-free Graft Survival [ Time Frame: Week 26 and 52 post transplantation ]
    Graft survival was defined as not having biopsy-proven acute rejection per Banff criteria, graft loss, or participant death. Participants who did not experience graft loss or death were censored at 365 days or the day they withdrew, whichever came first. There were no time-specific protocol mandated biopsies. Kidney biopsy would have been performed for cause at the discretion of the Investigator to assess poor graft function and would have been obtained prior to initiating treatment of suspected allograft rejection. Only summaries of Kaplan-Meier estimates of graft survival at Week 26 (Month 6) and Week 52 (Month 12) are reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female, 18 years or older
  • Has dialysis-dependent renal failure (initiated more than 2 months prior to transplant)
  • Participant is to receive a first kidney transplant from a standard criteria donor or expanded criteria donor deceased donor with a DGF risk score using the Irish scale of ≥25% (to be determined prior to surgery and before randomization)
  • Able to provide written informed consent
  • Willing and able to comply with the requirements of the study protocol
  • Female participants of child-bearing potential must have a negative serum pregnancy test (serum beta-human chorionic gonadotropin) and must be practicing an effective, reliable, and medically approved contraceptive regimen at the time of consent and for up to 5 months following discontinuation of treatment

Exclusion Criteria:

  • Participant to receive a multi-organ transplant
  • Participant to receive kidney(s) from donors <6 years of age
  • Participant to receive a dual kidney transplant (from same donor, including en bloc)
  • Participant to receive a living donor kidney
  • Participant is highly sensitized (high risk to develop acute antibody-mediated rejection) to the donor (as determined by local center practice). Testing to determine high risk may include but is not limited to flow cytometric cross match, single antigen bead testing and/or complement dependent cytotoxicity
  • Participant has received a previous transplant
  • Participant is participating in another investigational study
  • Participant has a body mass index >40 kilograms/square meter at screening
  • Participant will be the recipient of an A, B, O Blood Glycoproteins (ABO) (blood type) incompatible kidney (A2 donors to B and O recipients will be allowed if the site has the ability to confirm A2 subtype)
  • Participant will receive a kidney from a donation after cardiac death donor
  • Participant has a predicted Irish model risk of DGF <25%
  • Female participants who are pregnant or breast feeding
  • Female participants of child bearing potential who are unable or unwilling to use a medically acceptable form of contraception
  • Participants with a history of human immunodeficiency virus, or active hepatitis C virus or hepatitis B virus infection
  • Participants with active bacterial or other infection which is clinically significant in the opinion of the Investigator
  • Participants with a history of splenectomy
  • Participants with unresolved meningococcal disease
  • Participants with an unresolved systemic bacterial or fungal infection
  • Participants with known or suspected hereditary complement deficiency (for example, but not limited to: atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria)
  • Participant has a current malignancy or a history of any malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix that has been treated appropriately
  • Participant has a history of or is believed by the Investigator to have used an illicit drug(s) and/or abused alcohol within 3 months prior to screening
  • Participant has a psychiatric or physical illness that in the opinion of the Investigator would interfere with the ability of the participant to participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02145182


  Show 78 Study Locations
Sponsors and Collaborators
Alexion Pharmaceuticals
CTI Clinical Trial and Consulting Services

Layout table for additonal information
Responsible Party: Alexion Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02145182     History of Changes
Other Study ID Numbers: ECU-DGF-201
2013-004650-25 ( EudraCT Number )
First Posted: May 22, 2014    Key Record Dates
Results First Posted: December 17, 2018
Last Update Posted: December 17, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alexion Pharmaceuticals:
DGF
Dialysis
Kidney
Kidney Transplantation
eGFR
Complement
Eculizumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Delayed Graft Function
Pathologic Processes